Fatty acid synthase (FASN), an enzyme that drives de novo lipogenesis, plays a relevant role in metabolic disorders such as obesity, non-alcoholic fatty liver disease (NAFLD) or type 2 diabetes.

The sterol regulatory element-binding transcription factor 1 (SREBP-1), PPAR-γ coactivator-1α (PGC-1α), sirtuin 1 (SIRT1), fatty acid synthase (FASN), farnesyl-diphosphate farnesyltransferase 1 ...

Fatty acids are organic acids with at least one carboxyl (-C(=O)OH, -COOH or -CO2H) group and a long carbon chain that can be joined by double bonds, as in unsaturated fatty acids, or single bonds ...

9 to 11. The presentation will spotlight the company’s lead drug candidate, denifanstat, an oral, once-daily fatty acid synthase (FASN) inhibitor, which has shown promising results in the Phase ...

All metabolite identifications were performed using the in-house database (Shanghai Applied Protein Technology). 2.8 Acetyl coenzyme a carboxylase (ACACA), fatty acid synthase (FASN), and carnitine ...

(Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways ...

(Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways ...

Omega-3 fatty acids are one of two types of polyunsaturated fatty acids. Due to their anti-inflammatory properties, omega-3 fatty acids are considered the healthier type. Omega-3 fatty acids are found ...

The company's lead candidate, denifanstat, is an oral fatty acid synthase (FASN) inhibitor that has shown promising results in clinical trials for NASH treatment. Denifanstat has emerged as a ...